Shandong Xinhua’s Mixed Financial Performance in 2024

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.

Shandong Xinhua Pharmaceutical Company Limited reported a slight increase in operating income for the first nine months of 2024, reaching approximately RMB 6.73 billion, a 3.64% rise from the same period last year. However, the net profit attributable to shareholders saw a downturn, dropping by 12.22% to around RMB 344 million. Despite the decline in net profit, the company achieved a significant boost in net cash flow from operating activities, which surged by 233.45%.

For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.